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Background: Childhood uveitis is a rare inflammatory eye disease 
which is typically chronic, relapsing-remitting in nature, with an 
uncertain aetiology (idiopathic). Visual loss occurs due to structural 
damage caused by uncontrolled inflammation. Understanding of the 
determinants of long term outcome is lacking, including the 
predictors of therapeutic response or how to define disease control. 
Aims: To describe disease natural history and outcomes amongst a 
nationally representative group of children with non-infectious uveitis, 
describe the impact of disease course on quality of life for both child 
and family, and identify determinants of adverse visual, structural and 
developmental outcomes. 
Methods: UNICORNS is a prospective longitudinal multicentre cohort 
study of children newly diagnosed with uveitis about whom a core 
minimum clinical dataset will be collected systematically. Participants 
and their families will also complete patient-reported outcome 
measures annually from recruitment. The association of patient (child- 
and treatment- dependent) characteristics with outcome will be 
investigated using logistic and ordinal regression models which 
incorporate adjustment for within-child correspondence between eyes 
for those with bilateral disease and repeated outcomes 
measurement.  
Discussion: Through this population based, prospective longitudinal 
study of childhood uveitis, we will describe the characteristics of 
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childhood onset disease. Early (1-2 years following diagnosis) 
outcomes will be described in the first instance, and through the 
creation of a national inception cohort, longer term studies will be 
enabled of outcome for affected children and families.
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Background
Uveitis is a collective term for a varied group of rare conditions 
characterised by intraocular inflammation, in which uncon-
trolled disease can lead to irreversible ocular damage and visual 
loss1–3. It is less commonly seen in children than adults, with an 
estimated incidence of 5/100,000 children per annum2,4,5. Dis-
ease of childhood onset is typically chronic and relapsing-remit-
ting in nature, and often complicated by the co-occurrence of 
systemic inflammatory disease2,6,7. The primary intraocular 
location of the inflammation is used to classify uveitis type into 
anterior, intermediate, posterior and pan-(global)-uveitis8. The 
majority of affected children (between 40–90% dependent on 
the studied population) have chronic anterior disease2,9,10. Whilst 
up to half of childhood uveitis occurs as isolated ocular disease, 
uveitis can also be classified by the presence of an associated 
disorder8, the most common being juvenile idiopathic arthritis 
(JIA, a group of diseases with an estimated pooled prevalence of 
30 per 100,000)11. Infectious causes are also well recognised 
but uncommon2.
Affected children are managed with topical corticosteroids and 
systemic immunotherapies. Disease control is achieved in between 
30–70% by one year after diagnosis1–3,6,7,9,12. There are uncer-
tainties around the long-term outcomes for children with uvei-
tis, and the determinants of those outcomes. Several relatively 
large but methodologically heterogenous retrospective studies 
have reported conflicting findings on postulated predictors of 
ocular outcome or therapeutic response, including gender12–15, 
age at onset, disease duration, or serological markers such 
as anti-nuclear antibody (ANA)1,16–20. There are conflicting 
reports with regards to the beneficial or harmful role of topi-
cal steroids20,21, and the prognostic significance of low grade 
inflammation22,23. Consequently, there exists significant diver-
sity of practice and absence of consensus on the management of 
disease24.
In order to improve outcomes for children with non-infectious 
uveitis, we need to describe long term outcomes and their pre-
dictors. Existing work on the predictors of arthropathy outcomes 
for children with JIA suggests that these predictors may be 
clinical, demographic, environmental, psychological and or 
social25–29. We shall undertake a multi-centre, prospective incep-
tion cohort study, which aims to (1) describe disease natural his-
tory and outcomes amongst a nationally representative group 
of children with all-cause non-infectious uveitis, (2) describe 
the impact of disease course on quality of life for both child and 
family, and (3) identify determinants of therapeutic response, 
adverse visual, structural and developmental outcomes, and qual-
ity of life outcomes. We present the protocol for this study, the 




UNICORNS is a multicentre study which includes 26 secondary 
or tertiary care centres in the United Kingdom (UK) (see extended 
data - S130), although it will also be open to any hospital based 
paediatric ophthalmology service delivering care to children 
newly diagnosed with uveitis. Whilst participant identification 
and data sharing will occur across all sites, the primary research 
centre for the study will be the UCL Great Ormond Street 
Institute of Child Health.
Study population
Eligible children will be those aged under 18 years old (at diag-
nosis) who are newly diagnosed with uveitis. Exclusion crite-
ria for the study includes (1) uveitis due to malignancy, ocular 
trauma (including iatrogenic, ie intraocular surgery), or due to 
confirmed ocular infection. 
Recruitment
The families of eligible participants will be approached by 
their clinical team during the delivery of their routine care and 
informed of the study, and given contact details for the research 
team. Families will then contact the research team by email or 
by telephone to confirm their interest. A study video and study 
website have been established to support informed recruitment. 
Families will also contact researchers in person at sites where 
the research team are also members of clinical team. Families 
may also contact the research team electronically following noti-
fication of study via existing patient support groups which have 
agreed to support recruitment for this study (Olivia’s Vision, the 
largest uveitis patient group internationally). Following contact 
of the research team by the family, a study pack will be sent for 
completion. The study pack contains a participant information 
sheet, consent form, assent for young people, and a family back-
ground questionnaire which collects data on self-described eth-
nic background and the socioeconomic markers such as home 
ownership and parental educational attainment (see extended 
data - S230). On receipt of a completed consent form, the 
child’s clinical team and GP will be notified of the child’s 
recruitment.
Study procedures
Patient reported outcome measures (PROMs) will be collected 
from families at study entry and then annually over the duration 
of the study. The PROMs to be completed at baseline comprise:
- Strengths and Difficulties Questionnaire (SDQ): This is to 
screen the emotional and behavioural aspects of the participants 
lives. It comprises of 25 items split across 5 scales assessing 
emotional symptoms, conduct problems, hyperactivity-inattention, 
peer problems and prosocial behaviour31. It takes approximately 
5–10 mins to complete, and will be completed by children 
aged over 10 years, and by parents for children aged over 2 years. 
- Child Health Utility 9D (CHU9D): This is a brief (<5 mins to 
complete) generic preference based measure of health related 
quality of life, specifically developed with and for young 
people32. It is to be completed by children aged over 7 years 
and parents for those aged over 2 years.
- Children’s Sleep Habits Questionnaire (CSHQ): This evalu-
ates the incidence of behaviours linked with typical paediatric 
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sleep difficulties33, and takes an estimated 5 to 10 mins to com-
plete. It will be completed by children aged over 10 years, and by 
parents for children aged over 2 years.
- 100-mm general evaluation (GE): This visual analogue score 
(a horizontal line 100mm long) will be used to capture overall 
perception of the burden of the child’s uveitis. It will be com-
pleted by children aged over 5 years, and by parents for children 
aged 2–17.
At one year after diagnosis, and annually, children and their 
families will be invited to complete and return the following 
PROMS:
- 100-mm general evaluation (GE)
- Child Health Utility 9D (CHU9D)
- Paediatric Quality of life Score (PedsQL): This is used to 
evaluate health related quality of life in children. It is a brief 
questionnaire (typically 5 mins to complete) to be completed 
by children aged over 5 years, and parents of children aged over 
2 years.
- Vision related quality of life metric and Functional Vision 
Questionnaires for Children and Young People (VQoL_CYP 
& FVQ_ CYP): This pair of instruments captures the func-
tional and broader impacts of living with a visual disability24,34. 
They are self-completed for children over 8 years, and take 
15 minutes to complete.
Interim analyses will be undertaken to understand the corre-
lation between these PROMs, and in the event of strong cor-
relation indicative of instrument redundancy, the use of the 
PROMS will be rationalised during the study in order to limit the 
time spent by the families in completing them.
At baseline all families will also be asked to complete a family 
background form (approx. time for completion 5 minutes). Par-
ents of all children aged under 10 years will be asked (over the 
phone, or in person, approx. time for completion 5 – 10 minutes) 
for information available in pages of their child’s personal 
child health record (PCHR, or red book, current version in use 
since 2009). This information comprises perinatal adverse events, 
birth weight, vaccination history and any developmental con-
cerns. Consent will also be sought from participating families 
and young people for future linkage of cohort data to routine 
health, social care and education databases for collection of long 
term broad developmental and health outcomes.
All participating centres have agreed in principle to collect, for all 
children presenting with uveitis, and then at every clinic appoint-
ment, a standardised clinical dataset comprising the core clini-
cal and outcome variables (CCOV) (see extended data - S330). 
These comprise ocular and systemic clinical findings at pres-
entation, serological and imaging investigations undertaken, 
treatments prescribed to the children and degree of therapeu-
tic response, and clinical outcomes such as visual acuity of the 
development of a sight threatening complication. This will enable 
exploration of confounders of disease outcome such as severity of 
disease at onset, age at onset, disease duration, and use of immu-
nosuppression. Harmonisation work has been undertaken across 
sites ahead of study, to reach consensus on CCOV and the clini-
cal definitions in use. The CCOV will be incorporated into rou-
tine clinical notes in either paper or electronic format, thus 
avoiding additional administrative burden to the collaborat-
ing clinician. Data are to be returned via postal and/or elec-
tronic transfer, or direct from clinical records by the research 
team. Data will be pseudonymised (through use of an alphanu-
meric link code) prior to return. Acquired images of the affected 
eyes will also, where possible, be returned to the research team 
via secure NHS to NHS DICOM® (Digital Imaging and Com-
munications in Medicine) image sharing networks. Annual case 
note review by researchers at large volume centres (>5 children 
recruited per year) will occur to ensure completeness of data 
capture.
Sample size
Our aim is to study all eligible children diagnosed across this 
multicentre network, over a period of 3 years, with an expect-
ant consent rate of 60% and expectant attrition rate of 20%. This 
should result in a minimum of 250 children recruited over a three 
year period. This anticipated sample will allow us to reliably 
detect clinically important associations: at α=0.05, this sample 
size should >80% power to compare differences in proportions of 
at least 20% between groups. This assumes that the smaller group 
has at least 100 subjects35.
Outcome measures
These endpoints will be used, as measured every year following 
diagnosis:
Primary endpoints:
-    New incidence of sight threatening ocular complications, 
including glaucoma, cataract, and macular oedema
-    Quality of life
Secondary endpoints:
-    Total prescribed topical and systemic corticosteroid burden
-    Attainment of disease control (absolute control defined 
as absence of inflammation, relative control defined as 
the absence of inflammation greater than 0.5, the lowest 
grade of inflammation, with the use of less than one drop 
of topical corticosteroid)
The timeline for when these will be collected is provided in 
Table 1.
Statistical analysis
Patient demographic, socioeconomic and clinic characteris-
tics, and outcomes, will be described, as will the use of and tim-
ing of the different topical and systemic agents. Continuous 
variables will be reported as means with standard deviations or 
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medians with interquartile range. Categorical variables will be 
reported as proportions, with 95% confidence intervals. Outcomes 
will also be stratified by uveitis type (anterior versus other uvei-
tis, and JIA associated versus other uveitis), by age of onset, 
and by use of systemic therapy within the first six months 
following diagnosis.
The association of patient (child- and treatment- dependent) 
characteristics with outcome for the largest population (those 
with chronic anterior uveitis, expected to be 80% of the total 
group), will be investigated using logistic and ordinal regres-
sion models (STATA / R software) which incorporate adjust-
ment for time since disease onset. Multi-level modelling will be 
used for adjustment for within child correspondence between 
eyes for those with bilateral disease, and the clustered nature of 
repeated measures for this chronic disease.
Functional principal component analysis (FPCA) for sparse 
longitudinal data will be undertaken to investigate the differ-
ent trajectories of ocular inflammation amongst children with 
chronic anterior uveitis. The covariates used in this investiga-
tion will be those identified as potential mediators through the 
regression analyses. Where children have bilateral disease, the 
most severely affected eye will be selected for use in modelling. 
For those children with symmetrical bilateral disease, one eye 
will be chosen at random for inclusion. 
We shall also investigate the clustering of clinical findings within 
subtypes of all forms of uveitis disease using latent cluster 
analysis of demographic variables and clinical variables.
Ethics and dissemination
The study has been approved by the Health Research Authority 
Research Ethics Committee (IRAS 258638, REC 20/LO/0661). 
This study will be registered with ClinicalTrials.org.
The results from this study will be published on the institu-
tional website and published in peer reviewed journals. Study 
reports will be in accordance with the Strengthening the
Reporting of Observational Studies in Epidemiology State-
ment Guidelines (STROBE). Study newsletters will be made 
available online for participants and distributed through patient 
support groups. A study ‘Open Day’ will be held at the end 
of year 3 to inform participants on study progress and invite 
input on planned dissemination processes, with an online link 
to videos created during the day to involve those unable to 
attend on the day.
Patient and public involvement (PPI)
The study aims were informed by the priorities identified by 
stakeholders (patients and professional groups) who participated 
in the 2013 James Lind Alliance Priority Setting Partnership 
(JLA PSP)36. Amongst the top research topic priorities for those 
affected with inflammatory eye disease were the effectiveness 
of treatments, the ability to predict disease severity, the devel-
opment of early detection methods, and the safety of current 
monitoring for ongoing chronic uveitis. 
This study is supported by the Childhood Uveitis Studies Steer-
ing group (SSG), which was formed in April 2019 in order to 
provide ‘stakeholder’ guidance for study aims, methodology, 
and dissemination plans. The group consists of three young peo-
ple directly affected by childhood uveitis, and three parents of 
affected children. This group have been supported and trained 
in research methods through written materials / presentations. 
At least two SSG meetings have been held each year since 
group formation with email communications between meet-
ings. This group has co-developed the cohort study methods 
– e.g. selection of patient reported outcomes and study par-
ticipant literature. This study has also benefitted from regular 
communication with the UK based patient led support groups 
for childhood uveitis (Olivia’s Vision) and childhood arthritis 
(‘JIA matters / Versus Arthritis’).
Data storage and management.
Data are to be entered into study specific databases and manage 
by the research team (SK and ALS). All information collected 
during the course of the study will be kept strictly confidential. 
Forms will be anonymised and coded using a unique patient identi-
fier assigned at the notification stage. Stored patient information 
will be kept on NHS and University computers, so as to be able 
to track the patient in the study. All patient information will be 
managed according to Data Protection Act 2018 requirements.
Data availability
The datasets generated and/or analysed during the current 
study will be made available (following anonymization) by the 
Table 1. Timeline showing collection of patient reported 
outcome measures on recruitment to UNICORN.
Procedure Study Period




General health questionnaire x  
SDQ x  
CHU9D x x (x)
CHSQ x  
GE x x x
VQoL_CYP / FVQ_CYP x (x)
PedsQL x (x)
SDQ: strength and difficulties questionnaire; CHU9D: Child Health Utility 
9D; CSHQ: Children’s Sleep Habits Questionnaire; GE: 100-mm General 
Evaluation; PedsQL: Paediatric Quality of life Score; VQoL_CYP: Vision related 
quality of life metric – Children and Young People.
(x): in the event of strong correlation indicative of instrument redundancy, the 
use of these PROMS will be rationalised during the study in order to limit the 
time spent by the families in completing them.
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corresponding author on reasonable request. Authorised col-
laborators will be granted access to aggregated anonymised 
data from participants who have consented to this level of shar-
ing, following review of their study protocol. Requests will be 
reviewed by the research team and a patient representative. Data 
and material transfer agreements will be required to be com-
pleted, in order to ensure regulatory compliance and that the 
interests of the participants are upheld and respected throughout.
Resources created through study processes will be shared upon 
reasonable request.
Study status
The study is currently open to recruitment.
Discussion
Uveitis carries the risk of blindness and can result in life long 
burden of avoidable disability and the attendant high financial 
and social costs of medical care, education, rehabilitation and 
support needed for visually impaired children and the adults 
they become. Improved understanding of the factors associated 
with favourable and adverse outcomes for affected children are 
necessary for planning care and service provision. This mul-
ticentre study will result in a nationally representative cohort of 
children with non-infectious uveitis, providing externally valid 
findings on the determinants of outcome. The prospective col-
lection of patient reported outcome alongside an agreed minimal 
core clinical dataset will enable robust evaluation of the role of 
postulated risk factors with adjustment for identified confounding. 
It will also provide valuable information on the lived experience 
of these children, through the use of a range of patient reported 
measures. This allows UNICORNS to capture a more complete 
spectrum of patient centred outcomes than have been reported 
by previous studies. This study also offers a timely opportunity 
to investigate the outcomes of childhood uveitis in the United 
Kingdom at a time when more targeted, biologic agents such as 
adalimumab and tocilizumab have either been commissioned, 
or recommended for use in children with refractory disease37,38. 
Within trial populations, up to a quarter of children continue 
to have uncontrolled disease despite the use of these agents37. 
UNICORNS will provide information on the feasibility of under-
taking future ‘Trial within cohorts’ or other pragmatic interven-
tional trial designs, and provide a data sharing infrastructure 
to support ‘classic’ randomised controlled trials of emerging 
novel interventions. Greater understanding of this population of 
children affected by a rare, chronic, inflammatory, idiopathic 
disease will also allow investigators to develop future nested 
trials of complex interventions which are targeted at patient 
(eg, packages of support around the time of transition and trans-
fer to adult care), clinician (eg, decision support models for 
rare disease) or organisation level (eg, information sharing 
platform across primary and secondary care for rare disease). 
Thus, the findings of this cohort study will be of direct importance 
to clinical practice and future research within this disease area 
and beyond.
Limitations
This study design involves additional burden on the participants 
and their family through the completion of multiple carefully 
chosen and validated patient report metrics. These metrics 
characterise the family experience, global and vision related 
quality of life and health related utility. This allows for data 
collection on outcomes that our PPI work has shown to be of 
crucial importance to the affected families.
Observational studies such as UNICORNS are open to con-
founding, preventing causal inference when associations are 
reported. Our prospective design and use of a core minimal data-
set should enable careful consideration of identified potential con-
founders. In order to strengthen study findings, all study reports 
will be reported in accordance with STROBE guidelines.
Attrition is always a concern with regards to longitudinal stud-
ies. This study is supported by a national clinical network, the 
Paediatric Ocular Inflammation Group24,39, which will sup-
port follow up should children transfer from one clinical unit to 
another. The involvement of the child’s primary care giver, and 
the support of patient groups and their continued publication 
of study newsletters, is also expected to reduce attrition rates.
Summary
Childhood onset uveitis confers particular burden due to chro-
nicity, the association with systemic inflammatory disease, and 
the frequent requirement for systemic immunosuppression. 
There remain unanswered questions around disease phenotypes, 
long-term eye and wider developmental outcomes, and the deter-
minants of those outcomes, with resultant limitations in the evi-
dence base used to counsel affected families, balance treatment 
decisions, or plan further research. We propose a population 
based, prospective longitudinal study of childhood uveitis, in 
order to describe the characteristics of childhood onset disease. 
We will describe outcome and investigate socio-demographic, 
clinical, biological and treatment related determinants of outcome. 
Early (1–2 years following diagnosis) outcomes will be described 
in the first instance, and through the creation of a national incep-
tion cohort, we shall enable longer term studies of outcome for 
affected children and families. 
Ethics approval and consent to participate
This study is approved by the UK Health Research Authority. 
Patients or their legal representative will have to sign an informed 
consent form before study entry. This study is in accord-
ance with the Declaration of Helsinki and in accordance with 
the Medical Research Involving Human Subjects Act (WMO). 
Risks for participating in this study are expected to be very small 
to negligible and all patients will receive standard care. Objec-
tion or incapacitation of a patient or their representative will 
lead to exclusion from the study and analysis.
Data availability
Underlying data
No data are associated with this article.
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Extended data
Open Science Framework: UNICORNS extended data: https:// 
doi.org/10.17605/OSF.IO/EUBMA30 
This project contains the following extended data:
-    S1.pdf (List of collaborating centres)
-    S2.pdf (Study information pack)
-    S3.pdf (Minimal uveitis core dataset)
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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